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Abstract: Subcortical white matter hyperintensities (WMHs) in the aging population frequently
represent vascular injury that may lead to cognitive impairment. WMH progression is well described,
but the factors underlying WMH regression remain poorly understood. A sample of 351 participants
from the Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2) was explored who had WMH
volumetric quantification, structural brain measures, and cognitive measures (memory and executive
function) at baseline and after approximately 2 years. Selected participants were categorized into three
groups based on WMH change over time, including those that demonstrated regression (n = 96; 25.5%),
stability (n = 72; 19.1%), and progression (n = 209; 55.4%). There were no significant differences in age,
education, sex, or cognitive status between groups. Analysis of variance demonstrated significant
differences in atrophy between the progression and both regression (p = 0.004) and stable groups
(p = 0.012). Memory assessments improved over time in the regression and stable groups but declined
in the progression group (p = 0.003; p = 0.018). WMH regression is associated with decreased brain
atrophy and improvement in memory performance over two years compared to those with WMH
progression, in whom memory and brain atrophy worsened. These data suggest that WMHs are
dynamic and associated with changes in atrophy and cognition.
Keywords: white matter hyperintensities; WMH regression; WMH progression; Stable WMH; ADNI,
brain atrophy, cognition
1. Introduction
Magnetic resonance imaging (MRI) cerebral white matter hyperintensities (WMH) are non-specific,
subcortical signal regions with prolonged T2 relaxation times compared to normal appearing white
matter. They often appear conspicuously bright on T2-weighted images, particularly fluid-attenuated
inversion recovery (FLAIR) images where nearby bright cerebrospinal fluid intensity is suppressed.
Late-life WMH are thought to largely represent cerebrovascular injury resulting from cerebral small
vessel disease (cSVD) [1]. Such injury may lead to neuronal circuit dysfunction in affected areas
that can be associated with vascular cognitive impairment and dementia. Several previous studies
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demonstrate an association between progression of WMH lesion volume and worsening cognitive
impairment over time [2–5]. Although some studies have reported cases of WMH volume decrease
over time (regression), the relationship of these changes with cognitive outcomes needs to be further
evaluated [6,7]. To date, the only study that examined the relationship between the WMH regression
and structural brain changes and cognitive function is from the RUN DMC cohort [8]. The latter study
concluded that WMH regression group showed similar cognitive decline when compared to the WMH
stable group. In addition, WMH progression group showed more cognitive decline when compared to
the WMH stable group. Both WMH regression and stable groups showed no brain atrophy, suggesting
a relatively benign prognosis of such groups.
It is possible that WMH regression reflects imaging or methodological confounders rather than a
true biological phenomenon [9]. The use of standardized imaging sequences, scanners, and head coils
across longitudinal visits, in addition to regular scanner calibration and identical processing techniques
with uniform intensity corrections, such as that used in the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) study, are required to exclude analytic confounders and imaging artifacts that could
be interpreted as representing WMH regression. ADNI was launched in 2003 as a public/private
partnership designed to assess biological and clinical markers of Alzheimer’s Disease (AD) progression
(http://adni.loni.usc.edu).
Biologically, it is possible that regression of WMH volume represents gliotic contraction and/or
microvascular encephalomalacia resulting from static ischemic injury. If WMH regression represents
such a biological phenomenon, it could be associated with greater global brain atrophy and unchanged
or diminished cognitive function as occurs in many individuals post-stroke. Alternatively, WMH
regression might reflect a longitudinal reduction in inflammatory changes and focal edema associated
with cSVD, and if so, such changes should be associated with improved cognition despite a reduction
in total brain volume. Lastly, it is possible that WMH regression represents healing or regenerative
processes, that would be associated with reduced brain atrophy and improvement in cognitive
performance. A theoretical framework to summarize the course and interpretation of such longitudinal
changes are provided in Table 1.
The present study explored hypothetical mechanisms underlying WMH regression by examining
cognitive and structural brain changes (i.e., brain atrophy) that occur in the setting of WMH volume
regression through the analysis of longitudinal data collected as part of the ADNI 2 study.
Table 1. Possible etiologies for cerebrovascular-related white matter hyperintensities that regress over
time and the expected associations with cerebral atrophy and cognitive performance.
Possible Etiology for WMH Potential Cause of Regression Expected Associationwith Cerebral Atrophy
Expected Association with
Cognitive Performance
Irreversible ischemic injury Gliotic contraction and microscopicencephalomalacia Increased atrophy
No change in cognitive
performance
Inflammation associated
with irreversible ischemic
injury
Resolution of inflammation and
edema with restoration of normal
function in the penumbra
Increased atrophy
secondary to reduced
inflammatory edema
Improvement in cognitive
performance
Reversible ischemic injury Healing process Decreased atrophy Improvement in cognitiveperformance
2. Materials and Methods
2.1. Study Population
The study cohort was comprised of 351 ADNI 2 participants with normal cognition or mild
cognitive impairment who had WMH quantification both at baseline and at 2-years +/− 3 months [10].
Inclusion criteria included the availability of complete demographic information, diagnostic information
within 1 year of the T2 FLAIR scan used for WMH quantification at baseline, a T1-weighted (MPRAGE)
image and FreeSurfer structural segmentation [11,12] within 1 year of the baseline FLAIR images,
atrophy composite scores within 1 year of the baseline FLAIR images, and neurocognitive composite
metrics for assessments of both memory [13] and executive function (EF) [14]. Potential ADNI
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participants not meeting these criteria were excluded. The memory composite included the Rey
auditory verbal learning test (RAVLT), the cognitive component of the Alzheimer’s disease assessment
scale (ADAS-Cog), the Folstein mini-mental state examination (MMSE), and Wechsler logical memory
scale scores, whereas the executive function composite included the clock drawing test, trail making
test, category fluency (animal and vegetable), Wechsler adult intelligence scale-revised (WAIS-R) digit
span and digit symbol tests. Details of ADNI clinical procedures and methodology are available
elsewhere [15,16].
2.2. MRI Acquisition
FLAIR images were acquired according to standard ADNI protocols [15]. Scanning parameters
were identical within participants between the two-time points. As a result, the reported WMH
progression, stability, and regression measures fulfill the criteria needed to control for radiological and
methodological confounders [17]. Further information can be found at http://adni.loni.usc.edu.
2.3. White Matter Hyperintensity Calculations
WMH volumes were calculated using the 4-tissue segmentation method [18]. Briefly, FLAIR
images were co-registered to the T1 image, inhomogeneity-corrected and non-linearly aligned to a
minimal deformation template (MDT) using the T1 transformation and the FMRIB Software Library
(FSL) toolbox [19,20]. WMHs were estimated in MDT space using Bayesian probability and prior
probability maps [18]. Binary WMH masks were created using a threshold of 3.5 SD above the mean.
Volume of WMH were then calculated after back-transformation into native space. Gray, white, and
CSF measurements were segmented using an expectation–maximization algorithm. WMH were
ultimately subtracted from segmented white matter volume and reported in cubic millimeters.
2.4. Longitudinal Change Calculations
Changes in the various measures (∆) were calculated by subtracting the baseline value from the
value at the 2-year follow-up. Positive values indicate increases whereas negative values indicate
decreases between the two time points. For WMH volume change, a negative value greater than
150 mm3 indicates regression (i.e., less WMH volume at follow-up) whereas a positive value greater
than 150 mm3 indicates progression (i.e., more WMH volume at follow-up). Ten participants did not
have follow-up neurocognitive measures and 1 did not have ventricular volume within the 2 years +/−
3-month range; these values were excluded from further analyses.
2.5. WMH Categorization
WMH net volume change between the baseline and the follow-up visits was used to calculate
∆ WMH. Participants were initially grouped based on ∆ WMH volume (regression, stable, and
progression) using a percentile-based approach in which the percentile for no change was first
identified (the 35th percentile). Although definitions based on standard deviations were initially
considered, the notable leptokurtic distribution (Figure 1) of the data precluded such classification as
only the most extreme values would be defined outside of the stable group. Ultimately, we defined
the stable group as representing the +/− 10th percentile from the percentile of no change (25th–45th
percentile of the study participant distribution). This corresponded to +/− ∆ of 150 mm3 of WMH
lesion volume. Participants classified in the regression group had reductions in WMH volume greater
than 150 mm3 (more than 10 percentiles below the percentile of no change) and those classified in the
progression group had an increase in WMH volume greater than 150 mm3 (more than 10 percentiles
above the percentile of no change).
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from the four-tissue ADNI classification were combined to produce a total brain volume (cm3). 
However, this global measure alone does not specifically account for the volumetric changes in the 
ventricles, which is associated with both WMH changes [21] and AD-related neurodegenerative 
processes [22]. Therefore, the volume of the lateral ventricles (cm3) was estimated using FreeSurfer 
(University of California at San-Francisco, San-Francisco, CA, USA). Although these measures were 
assessed individually, the final measure was a composite that used the z-scores of brain volume 
Figure 1. White matter hyperintensity distribution in the sample studied. (A) The true distribution of
the data, showing notable leptokurtosis. Black arrows indicate standard deviation, demonstrating why
standard deviation was not deemed an appropriate criterion for separating groups. (B) Divisions of the
three white matter hyperintensity (WMH) groups. Visualization only.
2.6. Atrophy Composite Calculation
To quantitate changes in brain and ventricular volume to estimate changes in global brain atrophy
that may be related to WMH changes, gray and white matter segmentation volumes [18] from the
four-tissue ADNI classification were combined to produce a total brain volume (cm3). However, this
global measure alone does not specifically account for the volumetric changes in the ventricles, which is
associated with both WMH changes [21] and AD-related neurodegenerative processes [22]. Therefore,
the volume of the lateral ventricles (cm3) was estimated using FreeSurfer (University of California at
San-Francisco, San-Francisco, CA, USA). Although these measures were assessed individually, the
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final measure was a composite that used the z-scores of brain volume subtracted from the z-scores
from the lateral ventricles (higher value means less brain volume and/or larger ventricles). This was
done as an attempt to account for both periventricular and subcortical atrophy (ventricular volume) as
well as more cortical-based whole brain atrophy (brain volume).
2.7. Statistical Analysis
All statistical analyses were conducted using SPSS (version 24, SPSS Inc., Chicago, IL, USA).
All dependent variables were approximately normally distributed and screened for outlier removal.
Outliers were removed if they were 3 standard deviations outside the mean, specifically, three data
points in ∆ Memory, three in ∆ EF, seven in ∆ Ventricular Volume, and three in ∆ Brain Volume; any
outliers removed from the latter two were not entered into ∆ Atrophy.
ANOVAs were used to compare age and education between WMH progression, regression, and
stable groups. Pearson’s Chi Square was used to examine differences between groups in sex, marital
status, and cognitive status (normal, mild cognitive impairment [MCI], and AD). Between-group
differences in ∆ atrophy composite, ∆ ventricular volume, ∆ brain volume, ∆ memory, and ∆ EF
between the 3 groups were examined using ANCOVA with both age and sex as covariates. All statistics
were considered significant at p < 0.05 and were false discovery rate (FDR) corrected using the
Benjamini–Hochberg procedure [23].
3. Results
Participants were 72 ± 7.2 years old (48.3% women), with 16.5 ± 2.6 years of education. Clinical
cognitive status was normal in 40.2% and MCI in 59.8% (Table 2). There were no significant differences
between regression, stable, and progression groups in age, education, sex, marital status, diagnosis,
or ∆ EF. Participants were classified as having WMH regression in 25.5%, no change in 19.1%, and
WMH progression in 55.4%.
ANCOVA revealed that there were differences in ∆ atrophy composite between groups (p = 0.005),
particularly the progression and regression (p = 0.041) and the progression and stable groups (p = 0.003,
Table 2). Longitudinally, memory improved in the regression and stable groups compared to progression
(p = 0.036; p = 0.036 respectively, Table 3). There were no differences between any groups in ∆ EF
(p = 0.492, Table 3).
Table 2. Demographic, clinical, imaging, and change scores for subjects demonstrating progression,
stability, and regression in white matter hyperintensity volumes. WMH is reported in cubic centimeters;
Memory and executive function (EF) are reported in standardized scores, and Atrophy composite,
brain volume, and ventricular volume are z-scored. Raw scores for brain and ventricular volume per
group can be viewed in Table S1.
Criteria Progressors(n = 190)
Regressors
(n = 93)
Stable
(n = 68) Significance
n; (Progressors,
Regressors, Stable)
Age; (mean, SD) 72.2 (6.9) 72.0 (7.3) 70.3 (7.2) 0.163 190, 93, 68
Education; (mean, SD) 16.4 (2.6) 16.7 (1.6) 16.7 (2.4) 0.654 190, 93, 68
Female; (n, %) 98 (51.6) 40 (43.0) 34 (50.0) 0.393 190, 93, 68
Currently Married; (n, %) 140 (73.7) 72 (77.4) 50 (73.5) 0.764 190, 93, 68
Cognitively Normal; (n, %) 71 (37.4) 38 (40.9) 32 (47.1) 0.371 190, 93, 68
MCI (n, %) 119 (62.6) 55 (59.1) 36 (52.9) 0.371 190, 93, 68
Baseline WMH; (mean, SD) 6.9 (10.3) 8.2 (10.6) 1.9 (2.0) - 190, 93, 68
Follow Up WMH; (mean, SD) 8.7 (11.6) 6.9 (9.5) 1.9 (2.0) - 190, 93, 68
∆ Memory; (mean, SD) −0.07 (0.35) 0.02 (0.32) 0.05 (0.32) - 184, 89, 65
∆ EF; (mean, SD) −0.06 (0.59) 0.00 (0.62) 0.04 (0.56) - 182, 90, 65
∆ Atrophy Comp; (mean, SD) 0.19 (1.40) −0.17 (1.36) −0.52 (1.08) - 179, 90, 63
∆ Brain Volume; (mean, SD) −0.07 (0.90) 0.15 (1.0) 0.18 (0.78) - 187, 93, 68
∆ Ventricular Volume; (mean, SD) 0.12 (0.94) −0.08 (0.69) −0.34 (0.65) - 182, 90, 63
Abbreviations: n, number; SD, standard deviation; MCI, mild cognitive impairment; AD, Alzheimer’s disease;
WMH, white matter hyperintensities; EF, executive function composite.
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Table 3. ANCOVA results examining brain volume composite, memory change, and EF change in all
three groups. Age and gender were used as covariates.
ANCOVA Post-Hoc Comparisons p-Value p-Value (FDR-Corrected)
Dependent Variable
∆ Memory 0.017 * 0.028 *
Progression/Regression 0.024 * 0.036 *
Progression/Stable 0.019 * 0.036 *
Regression/Stable 0.766 0.766
∆ EF 0.492 0.492
Progression/Regression 0.398 0.398
Progression/Stable 0.293 0.293
Regression/Stable 0.790 0.790
∆ Atrophy Composite 0.001 ‡ 0.005 **
Progression/Regression 0.027 * 0.041 *
Progression/Stable 0.001‡ 0.003 **
Regression/Stable 0.172 0.172
∆ Ventricular Volume 0.011 * 0.028 *
Progression/Regression 0.036 * 0.054
Progression/Stable 0.007 ** 0.021 *
Regression/Stable 0.443 0.433
∆ Brain Volume 0.061 0.076
Progression/Regression 0.054 0.090
Progression/Stable 0.060 0.090
Regression/Stable 0.887 0.887
* indicates significant at p < 0.05. ** indicates significant at p ≤ 0.01. ‡ indicates significant at p ≤ 0.001. Abbreviations:
WMH, white matter hyperintensities; EF, executive function composite.
4. Discussion
These data indicate that WMH regression is associated with decreased brain atrophy and cognitive
decline over a period of two years compared to WMH progression, which, consistent with prior reports,
is associated with increased brain atrophy [24] and cognitive decline [25–27] (Table 2 and Figure 2).
WMH progression and regression have been reported in smaller cohorts [6,7,22,28], and a stable
group has also been identified in other studies [7,8,22]. Several studies reported that WMH progression
is associated with greater cognitive decline [4,5,8]; however, only one study reported on the potential
associations between WMH regression and changes in global atrophy or cognitive test performance
over time. The latter study showed that WMH regression was not associated with brain atrophy and
was associated with cognitive decline similar to that seen in the WMH stable group, suggesting a
relatively benign cognitive outcome [8].
Our data shows that, although there were significant differences in atrophy and cognition between
those with WMH progression and regression, and between those with progressive and stable WMHs,
there were no differences between those with WMH regression and stability. Both WMH progression
and regression groups had larger baseline WMH volume than the stable group. This implies that at
least some of those with WMH injury can return toward a normal functioning state.
We used the conventional net change in the WMH between the baseline and the follow-up visits
together with the percentile approach to categorize the dynamic changes into three groups (progression,
stable, and regression). We found that about 25.5% of study participants showed WMH regression,
which is similar to the 11.3% and 21.5% reported by others [8,29]. In addition, 19.1% of the cohort
remained stable and 55.4% showed WMH progression over two years. These data add to the existing
literature suggesting that WMH volume change is a dynamic process.
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Figure 2. Descriptive figure showing the dynamic nature of the white matter hyperintensity changes
over time and the a sociated change in brain volume and cognitive p rformance. The coro al image
cartoon represents the brain and ventricle size (scale of change exaggerat d for e phasis), while the
battery represents memory perform ce (improved memory corresponding to more battery capacity
and green). The first column rep esents a normal brain with no WMH and normal memory, the second
and third colum s the baseline and two-year follow up showing changes over the course of the study.
The upper row represents WMH stability. Brain volume and memory remained st ble in the follow
up visi as shown in A2 and A3. The middle row illustrates the case of progression of WMH over
time. In B3, the WMH region enlarges, brain volum decreases along wi h ventricular increa es and
memory declin s compared to B2. Finally, the lowe row represents c of WMH regression over
time. In C3, the WMH lesion v lume shrinks, brain volume is maintain d, and memory is improv d
when c mpared to C2.
We had several possible hypotheses regarding possible explanations for WMH regression. First,
it could be due to imaging acquisition or methodological confounders such as the use of different
scanners across visits, lack of scanner calibration, lack of standardized acquisition parameters,
differences in post-acquisition processing techniques such as registration or segmentation pipelines,
all of which may affect the accuracy of the WMH volume change calculation [9]. Use of the ADNI
cohort and WMH volumes from the validated UCD four-tissue segmentation method for this study
minimized such effects, suggesting instead that the observed dynamic nature of longitudinal WMH
volume changes reflects a real biological phenomenon.
Biological causes for WMH regression could include gliotic scarring and microstructural
encephalomalacia due to irreversible ischemic parenchymal injury, resolution of secondary
inflammatory processes as a result of irreversible ischemic damage, or could instead reflect resolution
or healing of reversible ischemic injury. The associations of WMH regression with measures of global
cerebral atrophy and cognitive change over time would be expected to differ between these possibilities
as highlighted in Table 1 and Figure 3.
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a scenario, acute small subc rtical strokes and lacunar inf rcts, which mimic WMH, could account for
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and focal edema related to irreversible ischemic injury. This hypothesis is supported by prior work
demonstrating that parenchymal edema develops ea ly during the WM vasc lar injury process [31].
Sev ral studies supporting the concept of resolving edema as an explanation for WMH regression are
bas d on observations in patients with cereb al autosomal dominant arteriopathy with subcortical
infarcts and leuko ncephalopathy (CADASIL) or stroke [32]. If this possibility were responsible
for WMH regressi n, measures of atrophy would increase in the etting of WMH regression as
inflammatory edema resolved, and cognitive functio would likely stabilize r improve. Although
this is a possibility for some WMH lesions, the overall lack f increased trophy argues against this
mechanism a a primary determinant of WMH r gression.
Lastly, it i possible that WMH regression is mo t closely related to resolution of reversible
ischemic changes or to healing or regene ative proce ses after such injury. In such a sce ario, WMH
regression would be ass ciated with ither no change or increased brai volume, and would also be
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associated with improvement in cognitive test performance. This hypothesis is best supported by
our observations.
Our data highlight the importance of considering WMH change over time as a dynamic process,
which can be related to both positive and negative structural and cognitive outcomes. Future work
should explore the many demographic, risk, and treatment variables that may have influenced
longitudinal WMH change in our cohort of subjects, perhaps suggesting disease modifying strategies to
prevent or reverse vascular cognitive impairment and dementia. Further longitudinal studies are also
needed to determine if there is interchange between groups—alternation between WMH progression
and regression states over time for example.
Limitations of the study involve time of observation in a chronic process, generalizability, and
sensitivity of measures. The ADNI cohort has unique characteristics based on its inclusion/exclusion
criteria, which include an emphasis on earlier stage disease including normal and MCI subjects as
well as criteria that excludes those with significant cerebrovascular disease and/or CVD risk factors.
As such, the cohort is not generalizable to epidemiologic and community-based cohorts that may have
higher proportions of cognitively impaired individuals and/or those with increased cerebrovascular
risk factors and/or WMH burden. We used global net change in the WMH between the baseline and
the follow up visits, limiting our ability to detect regional change in WMH progression, stability,
or regression compared to more detailed spatial location analyses used by others previously [22].
Finally, we only used two time points for demonstrating the dynamic nature of WMH; more sampling
of the time evolution curve of WMH is desirable in future.
Despite these limitations, the present study allowed an exploration of cognitive and brain volume
changes that are associated with dynamic WMH changes. The present data demonstrate that WMH
regression is not a mere imaging artifact or artifact due to methodologic procedures, but rather
represents a real biological phenomenon that may, at least in part, reflect recovery from and resolution
of reversible cerebrovascular injury.
5. Conclusions
Our data indicate that WMH regression is present in at least a quarter of this ADNI sample.
Those with WMH regression had a reduction in cognitive decline and decreased brain atrophy compared
to those with WMH progression, with no differences in either atrophy or memory performance between
the regression and stable groups. Identifying the underlying mechanisms that result in WMH regression,
and how these mechanisms may be promoted to produce more favorable clinical outcomes should be
further investigated.
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